Evidence map›Paper›PMID 30851984›Full record

ArticleEuropean urology2019

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.

Jaegil Kim, David Kwiatkowski, David J McConkey, Joshua J Meeks, Samuel S Freeman, Joaquim Bellmunt, Gad Getz, Seth P Lerner

Abstract read
PubMed Publisher
In one paragraph

Article in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 2 pooled it
23.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Jaegil KimThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
David KwiatkowskiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
David J McConkeyGreenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA.
Joshua J MeeksDepartment of Urology and Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.
Samuel S FreemanThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Joaquim BellmuntPSMAR-IMIM Laboratory, Bladder Cancer Center, Department of Medicine, Dana-Farber Cancer Institute and Harvard University, Boston, MA, USA.
Gad GetzThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Seth P LernerScott Department of Urology and the Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA. Electronic address: slerner@bcm.edu.
Broad Institute · USBaylor College of Medicine · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · USJohns Hopkins University · USNorthwestern University · US

Funding

The Role of EZH2 in Non-Muscle Invasive Bladder CancerI01BX003692 · VA · JESSE BROWN VA MEDICAL CENTER · PI Joshua James Meeks · 2017 to 2026
–
BLRD VA I01 BX003692
6 · The paper itself

Abstract

Analysis of the IMvigor 210 trials involving patients with platinum-refractory or cisplatin-ineligible urothelial carcinoma who were treated with the PD-L1 inhibitor atezolizumab identified a resistance signature as an immune biomarker. Transcriptome profiling of 368 tumor samples from this trial revealed that the "genomically unstable" Lund subtype classification was associated with the best response. We developed and applied a novel single-patient subtype classifier based on The Cancer Genome Atlas 2017 expression-based molecular subtypes. We identified 11 patients with a neuronal subtype, with a 100% response rate in eight confirmed cases (2 complete response, 6 partial response), and 72% overall, including 3/11 patients with an unconfirmed response. The survival probability was extraordinarily high for the neuronal subtype, which represents a high-risk cohort with advanced disease, and may be secondary to low levels of TGFβ expression and high mutation/neoantigen burden. PATIENT SUMMARY: We describe a methodology for genomic classification of an individual patient's bladder cancer tumor and have identified a subtype that is associated with a high response rate to immunotherapy. This is an important step forward in identifying the right treatment for the right patient, which is the goal of personalized precision medicine.

Indexed as

TranscriptomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Transitional CellGenomic InstabilityHumansPatient SelectionPrognosisSurvival RateUrinary Bladder NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalatezolizumabB7-H1 AntigenAnti-PD-L1 antibodyBladder cancerImmunotherapyNeuronalRB1SubtypesThe Cancer Genome AtlasTP53Urothelial cancer

Identifiers

PMID30851984
OpenAlexW2922520449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.